Allergic reactions to the first COVID‐19 vaccine: A potential role of polyethylene glycol?

  title={Allergic reactions to the first COVID‐19 vaccine: A potential role of polyethylene glycol?},
  author={Beatriz Cabanillas and Cezmi A. Akdis and Natalija Novak},
The COVID-19 vaccine developed by Pfizer and BioNTech was approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) on December 2nd 2020.1 MHRA is therefore the first regulator agency in the world to approve a vaccine to prevent coronavirus disease (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a virus that is responsible for a global pandemic. 
Allergic reactions to COVID‐19 ‐vaccinations – unveiling the secret(s)
This issue of Allergy features articles with current information on allergy‐related questions regarding COVID‐19 vaccination. Expand
COVID‐19 vaccines and the role of other potential allergenic components different from PEG. A reply to: “Other excipients than PEG might cause serious hypersensitivity reactions in COVID‐19 vaccines”
To the Editor, Thank you for the correspondence of Borgsteede et al “Other excipients than PEG might cause serious hypersensitivity reactions in COVID19 vaccines.”1 We agree with the authors andExpand
Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study
Several highly effective vaccines are available just over a year since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiologic agent of coronavirus disease 2019Expand
A Bullous Eruption following the Pfizer‐BioNTech COVID‐19 vaccination
On December 2nd,  2020 the Medicines and Healthcare products Regulatory Agency (MHRA) authorized use of a modRNA - nucleoside modified messenger RNA (mRNA) COVID-19 vaccine; Pfizer- BioNTech. PriorExpand
Practical handling of allergic reactions to COVID-19 vaccines
Recommendations for prophylaxis, diagnosis and therapy of these allergic reactions are given by a panel of experts, and allergy workup is recommended, as it is for a small potential risk population prior to the first vaccination. Expand
Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine?
The vaccination campaign against the Severe acute respiratory syndrome coronavirus 2 (Sars-Cov-2) started on 8 December 2020 in UK, after the approval of BNT162b2 by the Healthcare productsExpand
Adverse rare events to vaccines for COVID-19: From hypersensitivity reactions to thrombosis and thrombocytopenia
An updated review of the last scientific findings that can explain the rare side effects that the vaccines for COVID-19 can produce is provided. Expand
Allergy to COVID-19 vaccines: A current update
The different excipients in the vaccines with the potential to elicit systemic allergic reactions such as polyethylene glycol (PEG), polysorbates, tromethamine/trometamol, and others are described and the possible immunological mechanisms involved are described. Expand
ARIA‐EAACI statement on severe allergic reactions to COVID‐19 vaccines – An EAACI‐ARIA Position Paper
The current data have not shown any higher risk for patients suffering from allergic rhinitis or asthma, and this message should be clearly stated by physicians to enable patients to trust the vaccine. Expand
mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach
This review summarizes vaccine allergy epidemiology and proposes drug and vaccine allergy expert opinion informed risk stratification for Allergy specialist use in conjunction with guidance of public health and regulatory authorities. Expand


Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines. Expand
Immediate‐type hypersensitivity to polyethylene glycols: a review
  • E. Wenande, L. Garvey
  • Medicine
  • Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2016
This first comprehensive review provides practical information for allergists and other healthcare professionals by describing the clinical picture of 37 reported cases of P EG hypersensitivity since 1977, summarizing instances where PEG hypersensitivity should be considered and proposing an algorithm for diagnostic management. Expand
Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized.
Immediate hypersensitivity to PEG 3350 with cross-reactive polysorbate 80 hypersensitivity may be underrecognized in clinical practice and can be detected with clinical skin testing and raise the possibility of an IgE-mediated type I hypersensitivity mechanism in some cases. Expand
Polyethylene glycol as a cause of anaphylaxis
Potential life-threatening hypersensitivity reactions to hidden molecules like macrogol may be underdiagnosed and the awareness regarding the allergenic potential of PEG should be raised and a proper product labelling is crucial to prevent PEG mediated hypersensitivity. Expand
Polyethylene Glycol Induced Systemic Allergic Reactions (Anaphylaxis).
An algorithm is proposed to safely investigate suspected PEG allergy, with guidance on PEG molecular weights and skin test dilutions to minimize the risk of SAR. Expand
A case of anaphylaxis caused by macrogol 3350 after injection of a corticosteroid
Macrogols are polymers of ethylene glycol, and are widely used in food and food packaging, and also in cosmetics and pharmaceutical preparations as solvents, softening agents, and lubricants. Expand
Anti-PEG IgE In Anaphylaxis Associated with Polyethylene Glycol.